Opinion|Videos|March 14, 2025
Future Directions and Overcoming Challenges in BTK Inhibitor Therapy
Panelists discuss challenges oncologists face in managing treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including balancing efficacy with adverse effect profiles, and highlight strategies such as multidisciplinary collaboration and access to updated treatment guidelines to address these issues while also expressing eagerness for future advancements in Bruton tyrosine kinase (BTK) inhibitors and the need for further research to refine treatment strategies and improve patient outcomes.
Advertisement
Episodes in this series
- What are other challenges oncologists face when managing treatment-naive patients with CLL and MCL, and what strategies or resources can help overcome these challenges?
- What are you most eager to see regarding the future use of BTK inhibitors, and what areas of research or collaboration are needed to further improve patient outcomes?
Advertisement
Related to this article
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
This pilot study found that machine learning predicted post acute facility care (PAC) needs with 85% accuracy, demonstrating its feasibility and potential to help prioritize rehabilitation consultations early in hospitalization.
New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Across the US, Obesity Care Still Lacks an Owner
5